Relapsed Myasthenia Gravis after Nivolumab Treatment.

Abstract

Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.

• Authors: Ayumi Mitsune, Satoru Yanagisawa, Tatsuro Fukuhara, Eisaku Miyauchi, Mami Morita, Manabu Ono, Yutaka Tojo, Masakazu Ichinose
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 57 Issue 13 Pg. 1893-1897 (Jul 01 2018) ISSN: 1349-7235 [Electronic] Japan
• PMID: 29434145 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Nivolumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Female
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Middle Aged
• Myasthenia Gravis (chemically induced)
• Nivolumab